Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
SWOG Cancer Research Network
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06616584CT.gov Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | — | Recruiting | — | — | — |
NCT06632327CT.gov Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06749886CT.gov An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting | — | Recruiting | — | — | — |
NCT06421298CT.gov A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. | — | Recruiting | — | — | — |
NCT06228326CT.gov A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | — | Recruiting | — | — | — |
NCT06793813CT.gov Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT05834413CT.gov Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors | — | Recruiting | — | — | — |
NCT05633667CT.gov Study of Novel Treatment Combinations in Patients With Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05800587CT.gov Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | — | Recruiting | — | — | — |
NCT05096663CT.gov Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | — | Active Not Recruiting | — | — | — |
Show 57 more trialsShow fewer
NCT04863248CT.gov Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) | — | Terminated | — | — | — |
NCT04396535CT.gov Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04340882CT.gov Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade | — | Active Not Recruiting | — | — | — |
NCT04367311CT.gov Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) | — | Active Not Recruiting | — | — | — |
NCT03944980CT.gov Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer | — | Unknown | — | — | — |
NCT03971474CT.gov Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | — | Completed | — | — | — |
NCT03611738CT.gov Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | — | Active Not Recruiting | — | — | — |
NCT03703596CT.gov Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC | — | Unknown | — | — | — |
NCT03706703CT.gov Rh-Endostatin (Endostar®) Continuous Intravenous Infusion | — | Unknown | — | — | — |
NCT03411967CT.gov Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC | — | Unknown | — | — | — |
NCT02922764CT.gov A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | — | Completed | — | — | — |
NCT02326285CT.gov Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB | — | Terminated | — | — | — |
NCT02393248CT.gov Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | — | Terminated | — | — | — |
NCT01562301CT.gov Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC) | — | Withdrawn | — | — | — |
NCT01850147CT.gov Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen | — | Unknown | — | — | — |
NCT01207011CT.gov Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01059188CT.gov Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01209520CT.gov Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy | — | Completed | — | — | — |
NCT00771953CT.gov 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00937417CT.gov S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors | — | Withdrawn | — | — | — |
NCT00675597CT.gov Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00687297CT.gov Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00600496CT.gov A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | — | Completed | — | — | — |
NCT00520845CT.gov Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00539968CT.gov A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | — | Terminated | — | — | — |
NCT00465725CT.gov A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT00354562CT.gov A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00514293CT.gov Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00406276CT.gov Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00405951CT.gov Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00424840CT.gov Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy | — | Terminated | — | — | — |
NCT00312377CT.gov ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00313690CT.gov Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT00288054CT.gov S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00288444CT.gov Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | — | Terminated | — | — | — |
NCT01172028CT.gov Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00193453CT.gov Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00101907CT.gov Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer | — | Terminated | — | — | — |
NCT00222144CT.gov Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00077311CT.gov Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00114192CT.gov Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00274898CT.gov Celecoxib or Observation After Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00103389CT.gov Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00310154CT.gov Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00073866CT.gov Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00062270CT.gov Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00471432CT.gov OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | — | Completed | — | — | — |
NCT00054184CT.gov Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00040885CT.gov Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05) | — | Completed | — | — | — |
NCT00030641CT.gov Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00030407CT.gov Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00030420CT.gov Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00030810CT.gov Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC | — | Completed | — | — | — |
NCT00003103CT.gov Chemotherapy in Treating Patients With Solid Tumors | — | Completed | — | — | — |
NCT00004264CT.gov Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00080080CT.gov Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00021008CT.gov ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | SWOG Cancer Research Network | P3 | BB · 68 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Pancreatic Adenocarcinoma | — | P2 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docetaxel-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →